SC
REGN icon

Seldon Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Seldon Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-104
Closed -$75K – 207
2022
Q4 		$75K Hold
104
– – 0.06% 100
2022
Q3 		$72K Hold
104
– – 0.05% 104
2022
Q2 		$61K Hold
104
– – 0.04% 126
2022
Q1 		$73K Hold
104
– – 0.04% 127
2021
Q4 		$66K Buy
+104
New +$63.9K 0.04% 145

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Seldon Capital's REGN Position: Q1 2023 in Review

Seldon Capital sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 104 shares — an estimated $75K sold.

Seldon Capital first reported a position in REGN in Q4 2021 and held it in 5 quarters. The position peaked at $75K in Q4 2022. 1,191 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

  • Seldon Capital reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Seldon Capital sold 104 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $75K.
  • Seldon Capital first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • Seldon Capital's Regeneron Pharmaceuticals position peaked at $75K in Q4 2022.
  • 1,191 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on Seldon Capital's 13F filing for Q1 2023, filed 12 May 2023.